Search

Your search keyword '"Conrads, Kelly"' showing total 135 results

Search Constraints

Start Over You searched for: Author "Conrads, Kelly" Remove constraint Author: "Conrads, Kelly"
135 results on '"Conrads, Kelly"'

Search Results

2. Author Correction: Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities

3. Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities

4. Mapping three-dimensional intratumor proteomic heterogeneity in uterine serous carcinoma by multiregion microsampling

6. ProteoMixture: A cell type deconvolution tool for bulk tissue proteomic data

7. Peptide ancestry informative markers in uterine neoplasms from women of European, African, and Asian ancestry

8. Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer

9. Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatment

10. Multiomic analysis of uterine leiomyomas in self-described Black and White women: molecular insights into health disparities

11. Multi-omic Analysis of Uterine Leiomyomas in Self-Described Black and White Women: Molecular Insights into Health Disparities

12. Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways

14. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors

15. Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens

16. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer

17. Proteogenomic landscape of uterine leiomyomas from hereditary leiomyomatosis and renal cell cancer patients

18. ProteoMixture: A Cell Type Deconvolution Tool for Bulk Tissue Proteomics Data

19. Standardization and harmonization of distributed multi-center proteotype analysis supporting precision medicine studies

20. Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways

21. Additional file 1 of Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors

23. Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics

26. Proteomic Alterations Associated with Residual Disease in Neoadjuvant Chemotherapy Treated Ovarian Cancer Tissues

27. Molecular Correlates of Venous Thromboembolism (VTE) in Ovarian Cancer

28. Additional file 1 of Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues

29. Integrated multi-omic analyses reveals clinical relevance of endometrial cancer cell line models

30. Peptide Ancestry Informative Markers in Uterine Neoplasms from Women of European, African and Asian Ancestry

32. Standardization and Harmonization of Distributed Multi-National Proteotype Analysis supporting Precision Medicine Studies

33. Jupiter microtubule‐associated homolog 1 (JPT1): A predictive and pharmacodynamic biomarker of metformin response in endometrial cancers

34. Biomarker panel for early detection of endometrial cancer in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial

35. Extensive Intratumor Proteogenomic Heterogeneity Revealed by Multiregion Sampling in High-Grade Serous Ovarian Tumor Specimens

36. Abstract 4709: Extensive intratumor proteogenomic heterogeneity revealed by multiregion sampling in a high-grade serous ovarian tumor specimen

37. Hematological and Neurological Expressed 1 (HN1): a predictive and pharmacodynamic biomarker of metformin response in endometrial cancers

38. Jupiter microtubule‐associated homolog 1 (JPT1): A predictive and pharmacodynamic biomarker of metformin response in endometrial cancers.

40. Abstract 214: ARID1A and ARID1B dependent proteomics

42. NUAK1 (ARK5) Is Associated with Poor Prognosis in Ovarian Cancer

45. Abstract 4631: AKAP12 is elevated in paclitaxel-resistant ovarian cancer cells and correlates with poor ovarian cancer patient survival

46. Elevated AKAP12 in Paclitaxel-Resistant Serous Ovarian Cancer Cells Is Prognostic and Predictive of Poor Survival in Patients

48. Abstract 1570: ARID1A regulation of ATAD2 in gynecologic cancer

49. Abstract 2747: Pharmacological inhibition of the DNA damage response kinases, ATR (Ataxia telangiectasia and Rad3 related) and ATM (Ataxia telangiectasia mutated), broadly sensitizes diverse subtypes of gynecological cancer cells to ionizing radiation

50. Abstract 3377: Integrated molecular analysis of ovarian cancer cells identifies the ATR signaling axis central to cisplatin resistance.

Catalog

Books, media, physical & digital resources